Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

O. E. Rahma1, A. Duffy1, D. J. Liewehr2, S. M. Steinberg2 & T. F. Greten1*

1Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda; 2Biostatistics and Data Management Section, National Cancer Institute, Rockville, USA

Background: There is currently no standard of care for the second-line treatment of advanced pancreatic cancer. The aim of this analysis was to compare the different therapeutic approaches in this setting.

Methods: We carried out a systematic analysis of second-line studies in advanced pancreatic cancer that have progressed on or following gemcitabine and published or presented from 2000 to 2012.

Results: Forty-four clinical trials (t) were identified; of which 34 met the inclusion criteria treating an aggregate total of 1503 patients (n). Patients who received treatments (t: 33; n: 1269) had a median overall survival (OS) of 6 months compared with 2.8 months for patients who received best supportive care only (t: 2; n: 234) (P = 0.013). The gemcitabine and platinum-based combination (t: 5; n: 154) provided a median progression-free survival and OS of 4 and 6 months compared with 1.6 and 5.3 for the rest of the regimens (t: 29; n: 1349) (P = 0.059 and 0.10, respectively) and 2.9 and 5.7 for the combination of 5-fluorouracil and platinum agents (t: 12; n: 450) (P = 0.60 and 0.22, respectively).

Conclusion(s): Although not conclusive, these data showed that the advantage of second-line chemotherapy in pancreatic cancer is very limited and there is a need for more studies.

Key words: analysis, cancer, pancreatic, review, second-line, treatment

introduction

Pancreatic cancer has an estimated 5-year survival rate of 5%–6% and the majority of patients present with unresectable disease [1, 2]. For the past 10–15 years, gemcitabine has been considered the front-line chemotherapy in both locally advanced and metastatic disease due to its positive effect on quality of life and—to a lesser extent—overall survival [3]. While gemcitabine-based combinations have not been shown to be unequivocally more effective compared with gemcitabine alone, several analyses have suggested benefit in defined subpopulations such as patients with good performance status (PS) and metastatic disease [4–6]. Recently, FOLFIRINOX has emerged as an alternative to gemcitabine in the first-line setting after demonstrating superior survival outcome (median OS 11.1 versus 6.8 months, P < 0.001) [7]. However, this regimen is not suitable for patients with poor performance status (PS) and for these patients gemcitabine-based therapy will remain a favorable first-line option [7, 8]. In the second-line setting, there is no consensus on the optimal treatment. This is due, in part, to the paucity of trials in this patient population. In addition, only ≤50% of patients who fail first-line treatment are still physically fit enough to be offered second-line treatment [4, 7]. It has also not been unequivocally established that chemotherapy provides better efficacy compared with best supportive care (BSC), since studies that...
tried to address this question were underpowered and poorly designed [9, 10]. To further address these questions, we carried out a comprehensive analysis of the second-line trials in locally advanced or metastatic pancreatic cancer.

**Methods**

The primary objectives of this study were to determine whether treatment provides any superior effect over BSC and to determine the regimen that provides the best outcome. Secondary objectives were to compare the outcome of platinum-based compounds in combination with either gemcitabine or 5-fluorouracil (5-FU) and to determine the trend of treatment outcomes over time. We identified the data for this analysis by performing a PubMed search using the term 'second-line therapy AND advanced pancreatic cancer'. In addition, we reviewed the references of the relevant articles and the abstracts presented in ASCO, GI ASCO, ESMO, ECCO, and WCGC. Searches were limited to human studies published in English from 2000 to 2012. Exclusion criteria were trials that used chemotherapy other than gemcitabine in the first-line setting, novel investigational or targeted agents other than erlotinib in the second-line setting. Targeted agents were excluded since they represent a class of drugs with different mechanisms of action. However, since erlotinib is the only targeted agent that showed a survival benefit in the first-line setting [11], trials that used erlotinib were included. The following details were extracted: study start and completion dates, number of patients, second-line regimen, and outcomes, including the percentage of responders or the response rate (RR), the median progression-free survival (PFS), and overall survival (OS). In the trials that included more than one arm, each arm was analyzed separately.

**Statistical analysis**

For each trial or arm in the analyses, using results as presented in the relevant publications, the percentage who responded (RR), the median PFS and the median OS were obtained and used as the primary data being analyzed. In an exploratory manner, we compared the distributions of those three outcome variables (RR, PFS, and OS) according to the following categorical variables with the Wilcoxon rank sum test: BSC versus all others, 5-FU plus platinum agents versus all others (but excluding BSC), gemcitabine plus platinum agents versus all others (but excluding BSC), taxane-based regimens versus all others (but excluding BSC), erlotinib-based regimens versus all others (but excluding BSC), and gemcitabine plus platinum agents versus 5-FU plus platinum agents. Exact tests were used as appropriate. All reported P-values are two tailed. In view of the number of tests carried out, we considered P < 0.005 as statistically significant, while 0.005 < P < 0.05 indicated a strong statistical trend.

**Results**

The results of the search identified 38 published trials and 6 abstracts presented at scientific meetings. These 44 trials (t) comprised of 53 arms (a) and treated an aggregate total of 2384 patients (n). Out of these 44 trials, 7 used targeted therapy other than erlotinib [12–18], 2 used novel investigational chemotherapy [19, 20], and the efficacy data were not reported in one trial [7]. Therefore, only 34 trials met the inclusion criteria [9, 10, 21–52] comprising of 38 arms and treating an aggregate total of 1503 patients. The search results are summarized in Figure 1 and supplementary Table S1, available at Annals of Oncology online.

**BSC versus treatments**

In order to determine whether second-line treatment has any impact on outcome, we reviewed the clinical trials that included a BSC arm in their designs. Two phase III trials compared BSC to ‘active’ treatments [9, 10]. The first study by the German CONKO-study group was a phase III trial that randomized patients in a 1 : 1 ratio to BSC or OFF (oxaliplatin, folinic acid, and 5-FU) [10]. A total of 165 patients were required to demonstrate a statistically significant difference in survival.

---

**Figure 1.** Study selection. t, number of trials; a, number of arms; n, number of treated patients; BSC, best supportive care; 5-FU, 5-fluorouracil; Gem, gemcitabine. In the trial by Conroy et al., patients were randomized to two arms FOLFIRINOX or gemcitabine then received a second-line of gemcitabine if they progressed on FOLFIRINOX* or 5-FU-based regimen if they progressed on gemcitabine**.
However, only 46 patients were accrued and this trial was terminated early. Patients on the OFF arm (n: 23) had median OS of 4.82 months compared with 2.30 months in the BSC arm (n: 23) (P = 0.008). In the second study by Jacobs et al., the physician’s best choice (BC) including BSC (n: 211) was compared with rubitecan, an oral topoisomerase I inhibitor that showed promising activity in previous studies (n: 198) [9]. The majority of patients on the BC arm (89%) received alternative chemotherapy leaving only 11% of patients (n: 23) to receive BSC only. In addition, 49% of patients on the BC arm crossed over to the rubitecan arm at time of progression. This trial reported no significant difference in median OS between BC and rubitecan (3.3 versus 3.8 months, P = 0.62). Patients who crossed over to the rubitecan arm had a longer median survival compared with patients who did not (5.2 versus 2 months, P < 0.0001). In our analysis, we compared the outcomes of BSC in these two trials (a: 2; n: 234) to the outcomes of all treatments administered in the remaining 36 analyzed arms (a: 36; n: 1269). We found a trend toward an improved OS with treatments compared with BSC only (P = 0.013). However, there was no statistical difference in RR or PFS (P = 0.20 and 0.26, respectively) (Figures 2–4).

**5-FU in combination with platinum agents versus other treatments**

The combination of platinum agents and 5-FU has shown activity in several GI malignancies including esophageal, gastric, and colorectal cancers [53, 54]. We examined the activity of this combination in the second-line setting in

![Figure 2](https://example.com/figure2.png)

**Figure 2.** The response rate (RR) of each of the analyzed studies presented as dot plots. The three horizontal lines in each figure represent the quartiles of all the data combined. Circle size is proportional to the number of patients on each trial. The combination of gemcitabine (Gem) and platinum agents (Plat) provided a trend toward an improved RR (P = 0.006) compared with the other regimens.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** The median progression-free survival (PFS) of each of the analyzed studies presented as dot plots. The three horizontal lines in each figure represent the quartiles of all the data combined. Circle size is proportional to the number of patients on each trial. The combination of gemcitabine (Gem) and platinum agents (Plat) provided a trend toward an improved PFS (P = 0.059) compared with the other regimens.
pancreatic cancer. Twelve trials evaluated the efficacy of 5-FU in combination with either oxaliplatin or cisplatin, treating a total of 450 patients. Oxaliplatin was combined with either 5-FU—in 8 trials (n: 279) [10, 21, 22, 26–28, 31, 33]—or capecitabine—in 2 trials (n: 54) [29, 34]. Two trials used cisplatin in combination with either 5-FU (n: 100) [32] or S-1 (n: 17) [30]. The median number of treated patients per trial was 30 with a range of (15–100). Of these 12 trials, the CONKO-003 trial was the only phase III randomized study comparing OFF (oxaliplatin, folinic acid, and 5-FU) to FF (folinic acid and 5-FU) [22]. The CONKO-003 trial showed a survival benefit of adding oxaliplatin to 5-FU (5.89 versus 3.09 months, P = 0.01). In our analysis, the combination of 5-FU and platinum agents provided a median RR of 7% with a range of (0–29.4). The median PFS and OS were 2.9 and 5.7 months with a range of (0.9–5.8) and (1.3–10.7), respectively. The combination of 5-FU and platinum agents (a: 12, n: 450) did not show superior outcomes compared with the rest of the treatments (a: 26, n: 1053) in terms of RR, PFS or OS (P = 0.50, 0.27, 0.76, respectively) (Figures 2–4).

gemcitabine in combination with platinum agents versus other treatments

Combined analyses have suggested a potential survival benefit from adding platinum agents to gemcitabine compared with gemcitabine alone in the first-line setting in advanced pancreatic cancer [4–6]. We sought to determine the efficacy of this combination in the second-line setting. Five trials investigated the effect of adding platinum agents to gemcitabine after disease progression on gemcitabine, treating a total of 154 patients. Gemcitabine was combined with oxaliplatin in 2 trials (n: 50) [45, 49]; while the remaining three trials investigated the combination of gemcitabine with liposomal cisplatin (n: 24) [46], cisplatin plus 5-FU and epirubicin (n: 46) [47], or cisplatin plus 5-FU and irinotecan (n: 34) [48]. Gemcitabine was administered as a fixed dose rate (FDR) of 10 mg/m²/min in four trials [45, 47–49] and as a standard infusion rate over 30-min in one trial [46] (supplementary Table S2, available at Annals of Oncology online). The median number of treated patients per trial was 33 with a range of (17–46). The RR ranged from 8.3 to 24% with a median of 23%. The median PFS and OS were 4 and 6 months with a range of (2.4–5) and (4–10.3), respectively. When compared with other treatments (a: 33, n: 1349) the combination of gemcitabine and platinum agents (a: 5, n: 154) provided a trend toward an improved RR and PFS (P = 0.006 and 0.059, respectively) with no significant improvement in OS (P = 0.10). When compared with 5-FU in combination with platinum agents (a: 12, n: 450), the combination of gemcitabine and platinum agents (a: 5, n: 154) showed a strong trend toward an improved RR (P = 0.03) with no difference in PFS or OS (P = 0.60, 0.22, respectively) (Figures 2–4).

taxane-based regimens versus other treatments

Taxane-based chemotherapy is considered the standard of care in many malignancies including breast and lung cancers [55, 56]. We analyzed the activity of this treatment in the second-line setting in pancreatic cancer. Seven trials used taxane-based regimens treating a total of 223 patients. Of these seven trials, only one treated patients on two arms, irinotecan plus raltitrexed (n: 19) versus raltitrexed alone (n: 19) [38]. Taxane was used as a single agent in four trials (n: 108) [38–40, 44] and in combination with either capecitabine—in two trials (n: 55) [41, 43]—or irinotecan (n: 19) [38] or oxaliplatin (n: 41) [42]—in 2 trials. The median number of treated patients per trial was 21 with a range of (18–52). The RR ranged from 0 to 24% with a median of 8.7%. The median PFS and OS were 2 and 5.2 months with a range of (1.6–4) and (4.3–7.3), respectively. Our analysis showed no superior outcomes for taxane-based therapy (a: 8, n: 223) in comparison with other regimens (a: 30, n: 1280) in terms of RR, PFS, or OS (P = 0.81, 0.33, 0.59, respectively) (Figures 2–4).
erlotinib versus other treatments

Erlotinib is the only targeted agent that showed a survival benefit when combined with gemcitabine in the first-line setting [11]. In an attempt to identify the activity of this agent in the second line, we analyzed the three trials that used erlotinib in this setting and treated a total of 106 patients. One trial used erlotinib as a single agent (n: 50) [51], while two trials used erlotinib in combination with capcitabine (n: 30) [50] or bevacizumab (n: 26) [52]. The median number of treated patients per trial was 30 with a range of (26–50). The RR ranged from 0 to 10% with a median of 4%. The median PFS and OS were 1.6 and 4.1 months, respectively. Unexpectedly, there was a negative trend for RR and PFS over time while there was no change in OS.

treatment effect trend over time

Given the lack of progress in pancreatic cancer treatment, we analyzed the outcome trends over time in the second-line setting. We plotted the RR, PFS, and OS of each of the analyzed regimens over the last 13 years as shown in Figure 5. The earliest starting date of the studies was November 1997 and the latest ending date was August 2010. The median RR was 8.3%. The median PFS and OS were 2.9 and 6 months, respectively. Unexpectedly, there was a negative trend for RR and PFS over time while there was no change in OS.

discussion

There is currently no standard of care for locally advanced or metastatic pancreatic cancer that has progressed following either POFIRINNOX [7] or gemcitabine-based regimen [6, 11]. While there are potential options, there is no proven benefit for any regimen and treatment choice is generally an extrapolation from front-line studies. This comprehensive analysis indicates a benefit of treatment, mainly with the combination of gemcitabine and platinum agents, in patients who have progressed on gemcitabine in the first-line setting. Given the modest impact of chemotherapy in pancreatic cancer, the first question is whether there is a proven benefit associated with any therapy compared with BSC. In contrast to

---

**Figure 5.** The treatment outcome trends over time plotted against the month and the year of the studies including (A) the response rate (RR), (B) the progression-free survival (PFS), and (C) the overall survival (OS).
other GI malignancies such as colorectal and gastric cancers where the evidence of chemotherapy benefit over BSC in the second-line setting is established [57, 58], such evidence is lacking in pancreatic cancer. The German CONKO Group trial was stopped early due to insufficient accrual [10]. Likewise in the study by Jacobs et al., only 11% of the patients on the BC arm received BSC only (n: 23) with almost 50% crossover rate to the treatment arm [9]. In our analysis, the treatments provided a trend toward an improved OS compared with BSC only (median OS of 6 versus 2.8 months, P = 0.013). However, these results are limited by the small patient samples on the BSC arms and the lack of quality-of-life assessment on both of these trials. Indeed, randomizing patients to BSC will remain a challenge given this patient population’s poor prognosis.

Owing to the improvement in OS provided by the addition of oxaliplatin to 5-FU (n: 76) compared with 5-FU (n: 84) in the CONKO 3 study (5.89 versus 3.09 months, P = 0.010), this regimen has been widely used in the second-line setting [22]. In the CONKO 3 study, patients on the combination arm received more cycles of chemotherapy and had lower pain level assessment, which could be attributed to a better disease control. As expected, patients with good PS derived the most survival benefit. Although our analysis demonstrated no statistical significant improvement in outcomes of the 5-FU and platinum agents combination (α: 12; n: 450) compared with the rest of the regimens (α: 26, n: 1053), it did show a similar efficacy compared with gemcitabine and platinum agents combination (α: 5; n: 154) in terms of PFS and OS. Of note, these analyzed regimens used different platinum agents, 5-FU doses, and schedules.

Indeed gemcitabine remains the first-line treatment option for patients who are not candidates for FOLFIRINOX. However, the majority of patients develop resistance to gemcitabine in a short period of time suggesting a pre-existence of resistant cell subpopulations or stromal alterations [59, 60]. The combination of gemcitabine and platinum agents (α: 5; n: 154) was the only regimen that provided superior outcomes compared with the rest of the regimens (α: 33, n: 1349) in terms of RR and PFS (P = 0.006 and 0.059, respectively). However, the improvement in RR and PFS did not translate into a survival benefit (P = 0.10). This may have been influenced by subsequent treatments, the method of gemcitabine administration (FDR of 10 mg/min versus 30-min infusion standard rate), and the amount of cycles the patients were able to receive based on the regimen’s tolerability (supplementary Table S2, available at Annals of Oncology online).

Despite many efforts to improve the outcomes of the second-line treatments in advanced pancreatic cancer, these outcomes remain dismal. We demonstrated a worsening trend over the last decade in RR (median 8.3%) and PFS (median 2.9 months) with no change in OS (median 6 months) (Figure 5). One possibility to explain these trends is the incorporation of the RECIST criteria ‘Response Evaluation Criteria in Solid Tumors (RECIST)’ in the assessment of tumor response and time to progression in trials conducted after the year of 2000, resulting in a strict standardized evaluation of outcomes [61]. Noteworthy, neither PFS nor RR was found to be validated surrogate of OS in pancreatic cancer. It has been established that performance status and disease stage, locally advanced versus metastatic, have a major impact on outcome over any treatment effect in pancreatic cancer [62]. However, here we found no evidence for correlation between any of these variables and PFS or OS (data not shown).

To our knowledge, this is the first analysis to compare systematically the efficacy of the most widely used regimens in the second-line setting in pancreatic cancer. Our analysis is limited by the small sample size, the lack of randomization, the heterogeneity of the patients’ characteristics and regimens, and the exploratory nature of our statistical design. In addition, our data should be interpreted carefully due to the large selection bias since only ≤50% of patients who received first-line treatment qualified for a second line.

Furthermore, these second-line regimens have been used in patients who were not gemcitabine-naïve. This practice is likely to change since FOLFIRINOX became the standard first line in patients with good performance status. As a result, gemcitabine would become, by default, the standard second-line agent. Whether gemcitabine is the appropriate choice and whether it should be used as a single agent or in combination with other agents after FOLFIRINOX failure remains to be determined.

Novel approaches in pancreatic cancer treatment are desperately needed. There have been some advances in the recent years in the molecular and biological understanding of this disease. These advances include the discovery of the important role of the stroma in the drug delivery to the cancer cells [63], the diverse genetic alteration especially in metastatic disease [64], and the impact of stem cells on disease resistance to chemo and radiation therapy [65]. These discoveries may provide the future landscape of pancreatic cancer treatment.

In conclusion, our data support the use of chemotherapy over best supportive care in the second-line setting in pancreatic cancer. The combination of platinum agents with either gemcitabine or 5-FU is preferred in comparison with other regimens. However, the survival benefit provided by these combinations is limited and should be interpreted with caution given the selection bias in this patient population. There is a clear need for well-designed, randomized, and adequately powered clinical trials in the second-line setting after FOLFIRINOX failure. Indeed, future efforts must focus on individual therapy strategies including identifying genetic mutations and new biomarkers predictive of response, in addition to studying the molecular biology of these chemotherapy agents (i.e. ERCC-1, methylation of the MLH1 gene, RRM1). Nevertheless, exploiting recent understanding of the pancreatic tumor and stroma microenvironments in order to improve the therapeutic outcome in this disease is needed.

**funding**

This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
disclosure
The authors have declared no conflicts of interest.

references
17. O’Reilly EM. A phase II trial of sunitinib (S) in previously-treated pancreatic adenocarcinoma (PA), CALGB 80603. J Clin Oncol 2008; 26(Suppl); Abstr 4515.


